Reabilitação Cardiovascular em Contexto de Pandemia por SARS-CoV-2: Walking on Thin Ice

Afonso Rocha

Resumo


.

Texto Completo:

PDF

Referências


Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;382:e102.

Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, et al. Clinical characteristics and risk factors for mortality of COVID-19 patients with

diabetes in Wuhan, China: a two-center, retrospective study. Diabetes Care. 2020;43:1382-91.

Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 2020;41:2058-66.

Holman N, Knighton P, Kar P, O'Keefe J, Curley M, Weaver A, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8:823-33.

Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2016:CD001800.

European Association of Preventive Cardiology. Recommendations on how to provide cardiac rehabilitation activities during the COVID-19 pandemic. 2020 [accessed Oct 2020]. Available: https://www.escardio.org/Education/Practice-Tools/CVD-prevention-toolbox/recommendations-on-how-toprovide-cardiac-rehabilitation-activities-during-the-c




DOI: http://dx.doi.org/10.25759/spmfr.410

Apontamentos

  • Não há apontamentos.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Revista da Sociedade Portuguesa de Medicina Física e de Reabilitação